Gregory L. Weaver's Insider Trades & SAST Disclosures
Gregory L. Weaver's most recent trade in Altimmune Inc was a trade of 10,000 Common Stock, par value $0.0001 done at an average price of $5.2 . Disclosure was reported to the exchange on March 13, 2025.
Add Superstar Alert
Share
Note
This is a custom search result for pattern Gregory L. Weaver.To see full superstar portfolios of large investors like Warren Buffet, Elon Musk and others, click here.
Advanced/Help
"Balanced Fund": Use this format with quotation marks to find the exact phrase. The output matches
"Balanced Fund"
but not "Balanced Growth Fund"
Balanced Fund: Use this format without quotation marks to search for all funds related to the term
"Balanced Fund" The results may include
"Balanced Income Fund", "Balanced Growth Fund" and any fund name containing "Balanced Fund".
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| Altimmune Inc | Gregory L. Weaver | Chief Financial Officer | Purchase of securities on an exchange or from another person at price $ 5.20 per share. | 13 Mar 2025 | 10,000 | 10,000 (0%) | 0% | 5.2 | 51,996 | Common Stock, par value $0.0001 |
| Atossa Therapeutics Inc | Gregory L. Weaver | Director, EVP & CFO | Purchase of securities on an exchange or from another person at price $ 0.97 per share. | 20 Jun 2023 | 50,000 | 50,055 (0%) | 0% | 1.0 | 48,500 | Common Stock |
| Atossa Therapeutics Inc | Gregory L. Weaver | Director, EVP & CFO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Jun 2023 | 2,600,000 | 2,600,000 | - | - | Stock Option (right to buy) | |
| Atossa Therapeutics Inc | Gregory L. Weaver | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 13 May 2022 | 50,000 | 50,000 | - | - | Stock Option (right to buy) | |
| ATAI Life Sciences N.V. | Gregory L. Weaver | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Mar 2022 | 228,000 | 228,000 | - | - | Stock Option | |
| ATAI Life Sciences N.V. | Gregory L. Weaver | Chief Financial Officer | Purchase of securities on an exchange or from another person at price $ 15.00 per share. | 22 Jun 2021 | 4,666 | 4,666 | - | 15 | 69,990 | Common Shares |
| ATAI Life Sciences N.V. | Gregory L. Weaver | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 17 Jun 2021 | 67,726 | 67,726 | - | - | Stock Option | |
| ATAI Life Sciences N.V. | Gregory L. Weaver | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 17 Jun 2021 | 67,726 | 67,726 | - | - | Stock Option | |
| Atossa Therapeutics Inc | Gregory L. Weaver | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 14 May 2021 | 50,000 | 50,000 | - | - | Stock Option (right to buy) |
*All Values are in $ Million
Client Category: Promoter/ KMP/ Director / Immediate Relatives / Employee / etc
Security Type: Share/ Warrants / Convertible Debentures
Security Type: Share/ Warrants / Convertible Debentures
Data as reported to USA Exchanges